---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-416251"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2026-10-07T13:00:14+00:00"
generated_at: "2026-10-12T15:58:18.785941+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx to sell FDA-awarded PRV for $210M cash; 20% of proceeds owed to NIH

## Summary
- Asset purchase agreement signed Oct 6, 2026 to sell the Rare Pediatric Disease Priority Review Voucher awarded by FDA on Aug 19, 2026.
- $210 million payable in cash to Ultragenyx at closing; no buyer named in the filing.
- 20% of gross proceeds (~$42M) payable to the NIH under a patent license agreement dated Dec 10, 2018.
- PRV stemmed from FDA approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), or DTX401, for glycogen storage disease type Ia in patients 8 and older.
- Closing subject to customary conditions, including expiry or termination of the HSR waiting period; agreement to be filed with the FY2026 10-K.

## SEC filing metadata
- accession: 0001193125-26-416251
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2026-10-07T13:00:14+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000119312526416251/0001193125-26-416251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000119312526416251/rare-20261006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-416251
- JSON: https://secwatch.observer/filing/0001193125-26-416251.json
- Plain text: https://secwatch.observer/filing/0001193125-26-416251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.